Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC By Ogkologos - January 30, 2026 332 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASCENT-04/KEYNOTE-D19 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Why do non-smokers face delays in getting a lung cancer diagnosis? November 25, 2022 Pembrolizumab Improves Survival in Advanced Triple-Negative Breast Cancer August 9, 2022 Man Spent 20 Years Tracking Down And Buying His Late Mother’s... October 30, 2021 Rucaparib Approved as Maintenance Treatment for Some Recurrent Ovarian Cancers May 4, 2018 Load more HOT NEWS Talazoparib Does Not Prolong OS in BRCA1/2-mutated, HER2-negative Advanced Breast Cancer Regular Exercise May Boost Immune Response and Improve Immunotherapy in Breast... FDA Grants Regular Approval to fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic... Intratumoural Administration of the Oncolytic Herpes Virus Shows Survival Benefit and...
